Nowe wytyczne leczenia niewydolności serca 2021 Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2021
Słowa kluczowe:
wytyczne, niewydolność serca, inhibitory enzymu konwertującego, sakubitryl, walsartan, leki β-adrenolityczne, inhibitory receptora mineralokortykoidowego, inhibitory kotransportera sodowo-glukozowego
##plugins.themes.bootstrap3.article.main##
Abstrakt
Podczas tegorocznego kongresu ESC w Londynie ogłoszono aktualizację wytycznych dotyczących leczenia przewlekłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory. Główna zmiana w stosunku do wcześniejszych zaleceń polega na odejściu od długotrwałej strategii miareczkowania i stosowaniu prostszego i szybszego schematu opartego na czterech grupach leków: blokujących układ renina–angiotensyna–aldosteron (ACE-I, ARNI), inhibitorach kotransportera sodowo-glukozowego (dapagliflozyna, empagliflozyna), lekach β-adrenolitycznych, inhibitorach receptora mineralokortykoidowego.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Grabysa , R. (2021). Nowe wytyczne leczenia niewydolności serca 2021 . Medycyna Faktów , 14(4(53), 338-342. https://doi.org/10.24292/01.MF.0421.1
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-726. http://doi.org/10.1093/eurheartj/ehab368.
2. Brunner-La Rocca HP, Linssen GC et al. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. JACC Heart Fail. 2019; 7(1): 13-21. http://doi.org/10.1016/j.jchf.2018.10.010.
3. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014; 5(3): 53-61. http://doi.org/10.1177/2042018814544153.
4.Verma S, McMurray JJV, Cherney DZI. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiol. 2017; 2(9): 939-40. http://doi.org/10.1001/jamacardio.2017.1891.
5. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
6. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-200. http://doi.org/10.1093/eurheartj/ehw128.
7. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21): 1995-2008. http://doi.org/10.1056/NEJMoa1911303.
8. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15): 1413-24. http://doi.org/10.1056/NEJMoa2022190.
9. DeVore AD, Braunwald E, Morrow DA et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020; 5(2): 202-7. http://doi.org/10.1001/jamacardio.2019.4665.
10.Vaduganathan M, Claggett BL, Jhund PS et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020; 396(10244): 121-8. http://doi.org/10.1016/S0140-6736(20)30748-0.
11. Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021; 8(1): e001585. http://doi.org/10.1136/openhrt-2021-001585.
2. Brunner-La Rocca HP, Linssen GC et al. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. JACC Heart Fail. 2019; 7(1): 13-21. http://doi.org/10.1016/j.jchf.2018.10.010.
3. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014; 5(3): 53-61. http://doi.org/10.1177/2042018814544153.
4.Verma S, McMurray JJV, Cherney DZI. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiol. 2017; 2(9): 939-40. http://doi.org/10.1001/jamacardio.2017.1891.
5. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
6. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-200. http://doi.org/10.1093/eurheartj/ehw128.
7. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21): 1995-2008. http://doi.org/10.1056/NEJMoa1911303.
8. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15): 1413-24. http://doi.org/10.1056/NEJMoa2022190.
9. DeVore AD, Braunwald E, Morrow DA et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020; 5(2): 202-7. http://doi.org/10.1001/jamacardio.2019.4665.
10.Vaduganathan M, Claggett BL, Jhund PS et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020; 396(10244): 121-8. http://doi.org/10.1016/S0140-6736(20)30748-0.
11. Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021; 8(1): e001585. http://doi.org/10.1136/openhrt-2021-001585.